Crinetics Pharmaceuticals

Yahoo Finance • 10 days ago

Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that that Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics, will present at the 44th Annual J.P. Morgan... Full story

Yahoo Finance • 17 days ago

Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)

SAN DIEGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the first patient has been dosed in the CALM-CAH Phase 3 trial evaluating investigational candidate atumelnant, a novel, onc... Full story

Yahoo Finance • 18 days ago

Crinetics Pharmaceuticals (CRNX) Poised for Transformational Growth in 2026: Piper Sandler

Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) is one of the best biotech stocks to buy according to Wall Street analysts. On December 8, Piper Sandler reiterated that Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) is one of the stocks to own... Full story

Yahoo Finance • 26 days ago

Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors

SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the first patient has been dosed in the Phase 1/2 study evaluating CRN09682 in patients with metastatic or locally advanced somat... Full story

Yahoo Finance • last month

Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome

CAREFNDR underscores the potential clinical value of paltusotine beyond acromegaly, and demonstrates progress in Crinetics’ commitment to addressing unmet needs in the neuroendocrine tumor community SAN DIEGO, Nov. 20, 2025 (GLOBE NEWSW... Full story

Yahoo Finance • 2 months ago

Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on November 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purc... Full story

Yahoo Finance • 2 months ago

Crinetics Pharmaceuticals Inc Q3 Loss Increases, Misses Estimates

(RTTNews) - Crinetics Pharmaceuticals Inc (CRNX) reported Loss for its third quarter that increased from the same period last year and missed the Street estimates. The company's earnings came in at -$130.09 million, or -$1.38 per share.... Full story

Yahoo Finance • 3 months ago

Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on October 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purch... Full story

Yahoo Finance • 3 months ago

Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

SAN DIEGO, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report third quarter 2025 financial results on Thursday, November 6, 2025 after the market closes. Company managemen... Full story

Yahoo Finance • 3 months ago

Stocks Finish Higher as Core PCE Prices Match Expectations

The S&P 500 Index ($SPX [https://www.barchart.com/futures/quotes/$SPX/overview]) (SPY [https://www.barchart.com/etfs-funds/quotes/SPY/overview]) on Friday closed up +0.59%, the Dow Jones Industrials Index ($DOWI [https://www.barchart.com/f... Full story

Yahoo Finance • 3 months ago

Notable Friday Option Activity: TDOC, CRNX, WYNN

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Teladoc Health Inc (Symbol: TDOC), where a total of 35,521 contracts have traded so far, representing approximately 3.6 million un... Full story

Yahoo Finance • 3 months ago

Stocks Climb on Strength in Consumer Spending and Tame Inflation

The S&P 500 Index ($SPX) (SPY) today is up +0.56%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.81%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.28%.  December E-mini S&P futures (ESZ25) are up +0.53%, and December E-mini Nas... Full story

Yahoo Finance • 3 months ago

Stocks Turn Mixed as US Consumer Sentiment Slips

The S&P 500 Index ($SPX [https://www.barchart.com/futures/quotes/$SPX/overview]) (SPY [https://www.barchart.com/etfs-funds/quotes/SPY/overview]) today is up +0.10%, the Dow Jones Industrials Index ($DOWI [https://www.barchart.com/futures/q... Full story

Yahoo Finance • 3 months ago

Crinetics wins FDA approval for acromegaly therapy

[US Food and Drug Administration (FDA)] Crinetics Pharmaceuticals (NASDAQ:CRNX [https://seekingalpha.com/symbol/CRNX]) has received approval for its lead asset, Palsonify (paltusotine), as a first-line treatment for adults with acromegaly... Full story

Yahoo Finance • 3 months ago

Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly

Novel nonpeptide SST2 agonist PALSONIFY advances the treatment paradigm as the first once-daily, oral therapy approved by the FDA to treat acromegaly Approval based on data from two pivotal Phase 3 trials where PALSONIFY was well tolerate... Full story

Yahoo Finance • 3 months ago

Interesting CRNX Put And Call Options For November 21st

Investors in Crinetics Pharmaceuticals Inc (Symbol: CRNX) saw new options begin trading this week, for the November 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CRNX options chain for the n... Full story

Yahoo Finance • 4 months ago

Crinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on September 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to pu... Full story

Yahoo Finance • 4 months ago

Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH)

SAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for atumelnant, a novel, once-daily oral a... Full story

Yahoo Finance • 4 months ago

Tuesday's pre-market session: top gainers and losers

Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. [premarket] PRE-MARKET GAINERS TICKER CHANGE COMMENT LASE [https://www.chartm... Full story

Yahoo Finance • 5 months ago

Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on August 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purcha... Full story